Literature DB >> 7240156

Gelatin-binding domain-specific anti-human plasma fibronectin Fab' inhibits fibronectin-mediated gelatin binding but not cell spreading.

J A McDonald, T J Broekelmann, D G Kelley, B Villiger.   

Abstract

Antisera against a Mr = 60,000 peptide containing the gelatin-binding domain of human plasma fibronectin (McDonald, J. A., and Kelley, D. G. (1980) J. Biol. Chem. 255, 8848-8858) bound the Mr = 60,000 peptide and intact fibronectin but not three other fragments released by leukocyte elastase proteinolysis (the Mr = 25,000 amino-terminal sequence, Mr = 140,000 sequence containing cell adhesive activity, and a Mr = 31,000 fragment). Affinity-purified Fab' blocked Mr = 60,000 peptide binding to gelatin and inhibited plasma and cellular fibronectin gelatin binding without affecting fibronectin-mediated cell spreading. In contrast, antifibronectin Fab' absorbed with the gelatin-binding fragment completely blocked fibronectin-mediated cell spreading. These data indicate that the gelatin-binding domain of fibronectin is immunogenic, and antisera against this domain recognize cellular fibronectin gelatin-binding sites. Inhibition of gelatin binding but not cell spreading by anti-gelatin binding domain Fab' confirms the hypothesis that fibronectin has separate sites mediating these activities. Selective inhibition of fibronectin-collagen binding by domain-specific antisera may help elucidate the role of fibronectin in organization of the extracellular matrix.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7240156

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  In vivo and in vitro observations on laminin production by Schwann cells.

Authors:  C J Cornbrooks; D J Carey; J A McDonald; R Timpl; R P Bunge
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

2.  Interaction of fibronectin with collagen: age-specific defect in the biological activity of human fibroblast fibronectin.

Authors:  S Chandrasekhar; J A Sorrentino; A J Millis
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

3.  Inhibition of platelet aggregation by a monoclonal antibody against human fibronectin.

Authors:  V M Dixit; D M Haverstick; K O'Rourke; S W Hennessy; T J Broekelmann; J A McDonald; G A Grant; S A Santoro; W A Frazier
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

4.  Adsorption of fibronectin onto polymethylmethacrylate and promotion of Staphylococcus aureus adherence.

Authors:  P E Vaudaux; F A Waldvogel; J J Morgenthaler; U E Nydegger
Journal:  Infect Immun       Date:  1984-09       Impact factor: 3.441

5.  In vitro parasite-monocyte interactions in human leishmaniasis: possible role of fibronectin in parasite attachment.

Authors:  D J Wyler; J P Sypek; J A McDonald
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

6.  A monoclonal antibody to the carboxyterminal domain of procollagen type I visualizes collagen-synthesizing fibroblasts. Detection of an altered fibroblast phenotype in lungs of patients with pulmonary fibrosis.

Authors:  J A McDonald; T J Broekelmann; M L Matheke; E Crouch; M Koo; C Kuhn
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

Review 7.  Fibronectins: multifunctional modular glycoproteins.

Authors:  R O Hynes; K M Yamada
Journal:  J Cell Biol       Date:  1982-11       Impact factor: 10.539

8.  Role of fibronectin in collagen deposition: Fab' to the gelatin-binding domain of fibronectin inhibits both fibronectin and collagen organization in fibroblast extracellular matrix.

Authors:  J A McDonald; D G Kelley; T J Broekelmann
Journal:  J Cell Biol       Date:  1982-02       Impact factor: 10.539

9.  Specific binding of fibronectin--antifibronectin immune complexes to procollagen: a new pitfall in immunostaining.

Authors:  J A McDonald; D G Kelley
Journal:  J Cell Biol       Date:  1984-03       Impact factor: 10.539

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.